2-gene panel for autosomal dominant polycystic kidney disease.
A focused 2-gene panel for autosomal dominant polycystic kidney disease (PKD1, PKD2) — the most common inherited kidney disease.
GenDG §10
This is a predictive genetic test.
The order page will ask you to either book counseling or waive counseling in writing per German GenDG §10. Your choice is fully documented and accessible at any time.
HOW IT WORKS
How it works.
01
Easy at-home test
Order in three clicks, no login. Kit ships from Berlin within 5 working days.
02
Get your report and personalized action plan
Follow the guided sample collection. Your AI-interpreted clinical report arrives by secure email.
03
Consult with professionals and retest
Discuss findings with your physician or our medical geneticist; retest as your interventions evolve.
WHICH PART OF YOUR BODY
Which part of your body.
Kidneys
WHAT THIS PANEL ANSWERS
What this panel answers.
Do you carry inherited variants that cause autosomal-dominant polycystic kidney disease?
WHAT CHANGES IF A FINDING IS IDENTIFIED
What changes if something is found.
01Annual kidney-function monitoring is established practice -- eGFR, blood pressure, and abdominal ultrasound or MRI on a defined cadence.
02Tolvaptan can slow progression in selected patients and is prescribed by a nephrologist.
03Reproductive planning and family cascade testing are part of the standard follow-up.
04Without intervention, ADPKD typically progresses to end-stage kidney disease by the 50s or 60s; with active management, progression is significantly slowed.
Pathway references
GenDG §7
GENES ANALYZED
What is analyzed.
Atlas analyzes each gene in its entirety -- not just hotspot regions -- against current clinical literature. Findings are reviewed by a board-certified medical geneticist before release.
PRV13
Kidney Diseases
2 genes
A focused 2-gene panel for autosomal dominant polycystic kidney disease (ADPKD) -- the most common inherited kidney disease. PKD1 variants typically present earlier and progress faster than PKD2.
Analyzed genes -- 2 genesShow all genes →Hide genes ↑
PKD1
PKD2
Gene list per CeGaT PRV13 (2026-05).
WHY THIS MATTERS
Why early knowledge matters.
PRV13
Kidney Diseases
Kidney disease is often discovered only when function is already impaired. ADPKD now has a disease-modifying therapy -- tolvaptan -- that can slow progression in selected patients. Early genetic diagnosis enables a nephrologist to begin imaging surveillance and consider therapy at the right time.
RESULT INTERPRETATION
How findings are reported.
Every Atlas predictive report uses the same five-outcome framework so you and your physician can read it the same way each time.
01
Pathogenic variant
Increased disease risk. The report includes an individualized prevention plan and a recommendation to discuss next steps with a physician or medical geneticist.
02
Likely pathogenic variant
Probable disease association. Preventive monitoring is typically justified; the strength of evidence is documented in the report.
03
Variant of uncertain significance (VUS)
Reported but not currently actionable. A VUS may be reclassified over time as new evidence accumulates -- Atlas does not act on VUS findings without specialist review.
04
No relevant variant in this panel
No pathogenic or likely-pathogenic variant was identified in the analyzed genes. This does not eliminate all genetic risk -- only the genes in this panel were assessed.
05
Family implications
When an actionable variant is found, cascade testing of first-degree relatives is typically recommended -- a decision made together with a counselor.
Module-specific implications
PRV13
Kidney Diseases
—A confirmed finding is typically followed by renal imaging (ultrasound or MR) and a nephrology consult to evaluate eligibility for tolvaptan.
—Cascade testing is informative -- ADPKD is autosomal dominant.
Counseling and cascade testing
Predictive genetic testing in Germany requires consultation with a physician qualified in human genetics under §7 of the GenDG (Arztvorbehalt). Atlas Counseling provides this before and after the test. When an actionable finding has implications for relatives, your counselor will discuss cascade testing -- not Atlas alone.
CLINICAL LIMITATIONS
What this test does not do.
Not a diagnosis of active disease
A variant indicates predisposition. It does not confirm a condition is currently present.
Does not replace screening or routine care
Imaging, lab work, and physical examination remain part of clinical care. Atlas results inform them; they do not substitute for them.
Not all risk is genetic
Environment, behavior, age, and chance contribute to most common conditions. A genetic test reads one input.
A negative result does not eliminate risk
Only the genes on the panel were analyzed. Variants in other genes, in non-coding regions, and outside the assay's technical scope are not assessed.
Clinical decisions remain with your physician
Atlas reports are designed to be reviewed with a physician or medical geneticist. We do not recommend acting on a finding without that conversation.
GenDG §7
Predictive panels on this page are GenDG §7 Arztvorbehalt: counseling with a qualified human-genetics physician is required before and after the test. Atlas Counseling is included in the order flow.
Ready to start? €190 · 3–4 weeks after sample arrival